How to appeal a Premera Blue Cross plaque psoriasis + psoriatic arthritis denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for plaque psoriasis + psoriatic arthritis

Cited policy: BCBS Humira / Adalimumab Biosimilar PsA + Plaque PA

Plaque: BSA >=3% with special-site or BSA >=10% / PASI >=12 / DLQI >=10. PsA: ACR criteria + active disease (TJC/SJC >=3 or axial/enthesitis/dactylitis) + MTX failure or contraindication. Mandatory adalimumab biosimilar substitution (Cyltezo interchangeable preferred) unless dispense-as-written justification.

How Premera Blue Cross denies plaque psoriasis + psoriatic arthritis — and how to counter it

Where Premera Blue Cross pushes back: 1) MTX trial inadequate for PsA; 2) Must use Cyltezo/biosimilar instead of branded Humira; 3) BSA <3%; 4) Latent TB / HBV not screened.

Counter-arguments that hold up: ACR/NPF 2018 PsA (Singh) + GRAPPA 2021 + EULAR 2023 PsA — severe peripheral arthritis / axial / enthesitis / dactylitis / erosive disease can go directly to TNFi without MTX trial. SEAM-PsA: MTX inferior to etanercept wk 24. REVEAL (Menter JAAD 2008) PASI 75 71% wk 16. CHAMPION — Humira > MTX. For Cimzia: pregnancy-friendly (no Fc receptor → no transplacental transfer; Mariette ARD 2018). Biosimilar substitution acceptable but does NOT bypass primary-failure class-switch — failing branded Humira predicts failing biosimilar (same molecule).

What Premera Blue Cross typically denies for plaque psoriasis + psoriatic arthritis

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For plaque psoriasis + psoriatic arthritis, expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the plaque psoriasis + psoriatic arthritis treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Cimzia
• Simponi
• Cosentyx

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.